logo
Jobs Shrink in the Summer of '25, Pre-Markets Lower

Jobs Shrink in the Summer of '25, Pre-Markets Lower

Friday, August 1, 2025
The all-important Employment Situation report for July — nonfarm payrolls and unemployment — is out this morning, and results are far below projections: +73K new jobs were filled last month, lower than the +100K expected. The Unemployment Rate ticked up 10 basis points (bps) to 4.2%, which is still historically very good.
The initial takeaway from this report is the massive downward revisions to the prior two months: June dialed way back from +147K to 14K — including only +3K new jobs in the private sector — and May from +144K to +19K. The trailing 4-month average in nonfarm payrolls is now around -100K fewer per month than the prior 4 months. In short, it's a much weaker labor market this morning than we knew yesterday.
Hourly Wages still rose +0.3% for the month, as expected, up from +0.2% in June. Year over year, wages are +3.9%, up 10 bps from expectations, and +20 bps month over month. The Average Workweek ticked up to a still-lowish 34.3, but Labor Force Participation fell to 62.2% — not a strong number. The U-6 (aka "real unemployment") dipped a tad to 7.9%, relatively in-line with the historical average.
Let's address the Unemployment Rate a moment: at 4.2%, the appearance is that a satisfactory number of Americans are still gainfully employed. However, with retirees in both the Baby Boomer and now Generation X populations averaging around 90-100K per month, many in the workforce would take their most recent pink slip and not become part of the employed, but part of the newly retired. Thus, unemployment in the low 4% range may be a bit of a false indicator.
By sector, Healthcare brought in +55K new jobs last month — far and away the strongest industry for jobs currently. Social assistance gathered +18K. Manufacturing, on the other hand, spent its third straight month in negative territory, -37K, and the Federal Government has cut payrolls by -12K. Since President Trump has taken office in this term, the federal government workforce has shed -84K jobs.
Pre-Markets, Bond Yields Down; Fed Cut Probability Way Up
The timing of this jobs report in relation to the latest Fed meeting could have been better. When the Fed decided on Wednesday not to cut interest rates from their current +4.25-4.50% level, it was with the understanding the labor market had created +258K more jobs than we currently recognize. There is no Fed meeting in August — only an emergency meeting to cut rates would beget relief on interest rates before the next scheduled meeting in mid-September.
Depending on how the labor market performs over the next month and a half — not to mention what we see from the Inflation Rate and PCE reports (+2.7% and +2.6%, respectively, higher than previous months) — we may see a 25 bps or even a 50 bps rate cut come September. The likelihood of a cut ramped way up this morning, from around +34% ahead of the jobs report to +87% now.
The bond market has taken notice: the 10-year bond yield has fallen to +4.27%, more than half a percentage point since earlier this morning, and similarly on the 2-year, now +3.79%. Meanwhile, pre-market trading has sent major indexes into the red: the Dow is -330 points at this hour, the S&P 500 is -53 and the Nasdaq -220.
Q2 Earnings Friday Morning, at a Glance: XOM, CL & More
ExxonMobil XOM posted mixed results in its Q2 report ahead of today's opening bell. Earnings of $1.64 per share outshined the $1.49 analysts were expecting, for a +10% positive earnings surprise. Revenues, however, came in -1.59% below estimates. Oil supermajor rival Chevron CVX also beat earnings expectations, by +4% to $1.77 per share.
Colgate-Palmolive CL posted a 3-cent beat to 92 cents per share in its Q2 earnings report this morning, while beating on the top line by +1.17%. Dupixent maker Regeneron REGN had perhaps the biggest earnings beat of the morning, +60.5% to $12.89 per share in the quarter.
What to Expect from the Stock Market Today
We're not done with economic reports this Friday. S&P Manufacturing PMI for July is predicted to inch up month over month to 49.9 from 49.5 previously. This would bring this metric just to the precipice of growth, which is the 50 level. ISM Manufacturing, also for July, is expected to rise to 49.5% from 49.0% reported a month ago.
Construction Spending for June, Auto Sales for July and the final Consumer Sentiment print for July all come out after the regular trading day starts, as well. Construction spending is expected to improve but still show a negative -0.1%, while Consumer Sentiment is projected to meet the prior read of 61.8 — a good number.
Questions or comments about this article and/or author? Click here>>
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Chevron Corporation (CVX): Free Stock Analysis Report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strategy Announces $4.2 Billion Stock Sales Agreement
Strategy Announces $4.2 Billion Stock Sales Agreement

Globe and Mail

time38 minutes ago

  • Globe and Mail

Strategy Announces $4.2 Billion Stock Sales Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Strategy ( (MSTR)) has shared an announcement. On July 31, 2025, Strategy announced a sales agreement with several agents to issue and sell shares of its Variable Rate Series A Perpetual Stretch Preferred Stock, with an aggregate offering price of up to $4.2 billion. The company plans to use the proceeds for general corporate purposes, including the acquisition of Bitcoin and working capital. The sales will be conducted as an 'at the market offering' and are subject to terms and conditions outlined in the sales agreement. This move is part of Strategy's broader strategy to leverage its position in the digital asset market and enhance its financial flexibility. The most recent analyst rating on (MSTR) stock is a Buy with a $392.00 price target. To see the full list of analyst forecasts on Strategy stock, see the MSTR Stock Forecast page. Spark's Take on MSTR Stock According to Spark, TipRanks' AI Analyst, MSTR is a Neutral. The overall stock score of 48 reflects significant financial and valuation challenges, with high leverage and negative earnings outweighing positive strategic initiatives and Bitcoin-focused capital strategies. Despite a strong strategic focus on cryptocurrency and recent successful capital raising, the financial instability and legal risks pose substantial concerns. To see Spark's full report on MSTR stock, click here. More about Strategy MicroStrategy Incorporated, doing business as Strategy, is a publicly traded company recognized as the world's first and largest Bitcoin Treasury Company. It has adopted Bitcoin as its primary treasury reserve asset and strategically accumulates Bitcoin through equity and debt financings, as well as cash flows from operations. The company also provides AI-powered enterprise analytics software, integrating analytics expertise with digital asset growth, positioning itself as a leader in both the digital asset and enterprise analytics sectors. Average Trading Volume: 12,259,375 Technical Sentiment Signal: Buy Current Market Cap: $111.9B See more data about MSTR stock on TipRanks' Stock Analysis page.

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

Globe and Mail

time2 hours ago

  • Globe and Mail

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store